Uncategorized
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune. Read More
Uncategorized
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
The FDA has been trying to mend fences with rare disease drug developers and patient groups since the departure of former Commissioner Marty Makary three months ago. But advisory committee meetings last week for Replimune and Capricor Therapeutics only created more confusion and frustration.
Uncategorized
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
Uncategorized
STAT+: Moderna launches early trial of Ebola mRNA vaccine
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got a busy earnings week. Here’s the latest.
The need-to-know this morning
- Amgen and Gilead Sciences reported earnings last night.
- United Therapeutics reported earnings this morning.
Novo vs. Lilly
The two GLP-1 giants have both reported earnings.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got a busy earnings week. Here’s the latest.
The need-to-know this morning
- Amgen and Gilead Sciences reported earnings last night.
- United Therapeutics reported earnings this morning.
Novo vs. Lilly
The two GLP-1 giants have both reported earnings.
-
Fierce Biotech4 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Endpoints News5 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized4 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State